These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32988266)

  • 1. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
    Ladha A; Mannis G; Muffly L
    Leuk Lymphoma; 2021 Feb; 62(2):257-263. PubMed ID: 32988266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
    Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].
    Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K
    Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
    Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
    Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
    Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.
    Duncan C; St Martin A; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29067. PubMed ID: 33871892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
    Corbacioglu S; Jabbour EJ; Mohty M
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1271-1280. PubMed ID: 30797942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Kantarjian HM; Boissel N; Papayannidis C; Luskin MR; Stelljes M; Advani AS; Jabbour EJ; Ribera JM; Marks DI
    Cancer; 2024 Nov; 130(21):3631-3646. PubMed ID: 39093036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
    Cortes JE; de Lima M; Dombret H; Estey EH; Giralt SA; Montesinos P; Röllig C; Venditti A; Wang ES
    J Hematol Oncol; 2020 Oct; 13(1):137. PubMed ID: 33059764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
    Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
    Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
    Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
    Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
    Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
    Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
    McDonald GB; Freston JW; Boyer JL; DeLeve LD
    Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
    Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Sabatino D; Henneman A; Ahmad S; Jou E; Goldberg B
    J Oncol Pharm Pract; 2023 Jun; 29(4):840-845. PubMed ID: 35293248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
    Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
    Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
    Leopold LH; Berger MS; Feingold J
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.